First Tracks Biotherapeutics is trading at $45.92, up 5.61%, with the move coinciding with a strong biotech session.
- XBI was up 2.18%; no confirmed company-specific catalyst surfaced for the October 27 move.
- Recent positive ANB033 Phase 1b celiac-disease results and analyst support predate the session and do not establish its cause.
- The company’s latest reported news was its October 15 private placement.